Biomarkers Market

Biomarkers Market (Type: Susceptibility/Risk Biomarkers, Diagnostic Biomarkers, Prognostic Biomarkers, Monitoring Biomarkers, Predictive Biomarkers, Pharmacodynamic/Response Biomarkers, and Safety Biomarkers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Biomarkers Market – Scope of Report

TMR’s report on the global biomarkers market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global biomarkers market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global biomarkers market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the biomarkers market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global biomarkers market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global biomarkers market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global biomarkers market.

The report delves into the competitive landscape of the global biomarkers market. Key players operating in the global biomarkers market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global biomarkers market profiled in this report.

Key Questions Answered in Global Biomarkers Market Report
  • What is the sales/revenue generated by biomarkers across all regions during the forecast period?
  • What are the opportunities in the global biomarkers market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Biomarkers Market – Research Objectives and Research Approach

The comprehensive report on the global biomarkers market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global biomarkers market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global biomarkers market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Biomarkers Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Biomarkers Market Analysis and Forecast, 2017-2031
4.5. Porter’s Five Forces Analysis
5. Key Insights
5.1. FDA Approved Cancer Biomarkers
5.2. Biomarkers and Its Application in Cancer Research
5.3. Insights on Application of biomarkers in Drug Development
5.4. COVID-19 Pandemic Impact on Industry
6. Global Biomarkers Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017-2031
6.3.1. Consumables
6.3.2. Services
6.3.3. Software
6.4. Market Attractiveness Analysis, by Product
7. Global Biomarkers Market Analysis and Forecast, by Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Type, 2017-2031
7.3.1. Susceptibility/Risk Biomarkers
7.3.2. Diagnostic Biomarkers
7.3.3. Prognostic Biomarkers
7.3.4. Monitoring Biomarkers
7.3.5. Predictive Biomarkers
7.3.6. Pharmacodynamic/Response Biomarkers
7.3.7. Safety Biomarkers
7.4. Market Attractiveness Analysis, by Type
8. Global Biomarkers Market Analysis and Forecasts, by Disease Indication
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Disease Indication, 2017-2031
8.3.1. Cancer
8.3.2. Neurological Disorders
8.3.3. Cardiovascular Disorders
8.3.4. Infectious Diseases
8.3.5. Immune Disorders
8.3.6. Others
8.4. Market Attractiveness Analysis, by Disease Indication
9. Global Biomarkers Market Analysis and Forecast, by Application
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Application, 2017-2031
9.3.1. Diagnostics
9.3.2. Drug Discovery & Development
9.3.3. Personalized Medicine
9.3.4. Disease Risk Assessment
9.3.5. Others
9.4. Market Attractiveness Analysis, by Application
10. Global Biomarkers Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Country/Region
11. North America Biomarkers Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017-2031
11.2.1. Consumables
11.2.2. Services
11.2.3. Software
11.3. Market Value Forecast, by Type, 2017-2031
11.3.1. Susceptibility/Risk Biomarkers
11.3.2. Diagnostic Biomarkers
11.3.3. Prognostic Biomarkers
11.3.4. Monitoring Biomarkers
11.3.5. Predictive Biomarkers
11.3.6. Pharmacodynamic/Response Biomarkers
11.3.7. Safety Biomarkers
11.4. Market Value Forecast, by Disease Indication, 2017-2031
11.4.1. Cancer
11.4.2. Neurological Disorders
11.4.3. Cardiovascular Disorders
11.4.4. Infectious Diseases
11.4.5. Immune Disorders
11.4.6. Others
11.5. Market Value Forecast, by Application, 2017-2031
11.5.1. Diagnostics
11.5.2. Drug Discovery & Development
11.5.3. Personalized Medicine
11.5.4. Disease Risk Assessment
11.5.5. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Type
11.7.3. By Disease Indication
11.7.4. By Application
11.7.5. By Country/Sub-region
12. Europe Biomarkers Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017-2031
12.2.1. Consumables
12.2.2. Services
12.2.3. Software
12.3. Market Value Forecast, by Type, 2017-2031
12.3.1. Susceptibility/Risk Biomarkers
12.3.2. Diagnostic Biomarkers
12.3.3. Prognostic Biomarkers
12.3.4. Monitoring Biomarkers
12.3.5. Predictive Biomarkers
12.3.6. Pharmacodynamic/Response Biomarkers
12.3.7. Safety Biomarkers
12.4. Market Value Forecast, by Disease Indication, 2017-2031
12.4.1. Cancer
12.4.2. Neurological Disorders
12.4.3. Cardiovascular Disorders
12.4.4. Infectious Diseases
12.4.5. Immune Disorders
12.4.6. Others
12.5. Market Value Forecast, by Application, 2017-2031
12.5.1. Diagnostics
12.5.2. Drug Discovery & Development
12.5.3. Personalized Medicine
12.5.4. Disease Risk Assessment
12.5.5. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Type
12.7.3. By Disease Indication
12.7.4. By Application
12.7.5. By Country/Sub-region
13. Asia Pacific Biomarkers Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017-2031
13.2.1. Consumables
13.2.2. Services
13.2.3. Software
13.3. Market Value Forecast, by Type, 2017-2031
13.3.1. Susceptibility/Risk Biomarkers
13.3.2. Diagnostic Biomarkers
13.3.3. Prognostic Biomarkers
13.3.4. Monitoring Biomarkers
13.3.5. Predictive Biomarkers
13.3.6. Pharmacodynamic/Response Biomarkers
13.3.7. Safety Biomarkers
13.4. Market Value Forecast, by Disease Indication, 2017-2031
13.4.1. Cancer
13.4.2. Neurological Disorders
13.4.3. Cardiovascular Disorders
13.4.4. Infectious Diseases
13.4.5. Immune Disorders
13.4.6. Others
13.5. Market Value Forecast, by Application, 2017-2031
13.5.1. Diagnostics
13.5.2. Drug Discovery & Development
13.5.3. Personalized Medicine
13.5.4. Disease Risk Assessment
13.5.5. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Type
13.7.3. By Disease Indication
13.7.4. By Application
13.7.5. By Country/Sub-region
14. Latin America Biomarkers Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017-2031
14.2.1. Consumables
14.2.2. Services
14.2.3. Software
14.3. Market Value Forecast, by Type, 2017-2031
14.3.1. Susceptibility/Risk Biomarkers
14.3.2. Diagnostic Biomarkers
14.3.3. Prognostic Biomarkers
14.3.4. Monitoring Biomarkers
14.3.5. Predictive Biomarkers
14.3.6. Pharmacodynamic/Response Biomarkers
14.3.7. Safety Biomarkers
14.4. Market Value Forecast, by Disease Indication, 2017-2031
14.4.1. Cancer
14.4.2. Neurological Disorders
14.4.3. Cardiovascular Disorders
14.4.4. Infectious Diseases
14.4.5. Immune Disorders
14.4.6. Others
14.5. Market Value Forecast, by Application, 2017-2031
14.5.1. Diagnostics
14.5.2. Drug Discovery & Development
14.5.3. Personalized Medicine
14.5.4. Disease Risk Assessment
14.5.5. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Type
14.7.3. By Disease Indication
14.7.4. By Application
14.7.5. By Country/Sub-region
15. Middle East & Africa Biomarkers Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017-2031
15.2.1. Consumables
15.2.2. Services
15.2.3. Software
15.3. Market Value Forecast, by Type, 2017-2031
15.3.1. Susceptibility/Risk Biomarkers
15.3.2. Diagnostic Biomarkers
15.3.3. Prognostic Biomarkers
15.3.4. Monitoring Biomarkers
15.3.5. Predictive Biomarkers
15.3.6. Pharmacodynamic/Response Biomarkers
15.3.7. Safety Biomarkers
15.4. Market Value Forecast, by Disease Indication, 2017-2031
15.4.1. Cancer
15.4.2. Neurological Disorders
15.4.3. Cardiovascular Disorders
15.4.4. Infectious Diseases
15.4.5. Immune Disorders
15.4.6. Others
15.5. Market Value Forecast, by Application, 2017-2031
15.5.1. Diagnostics
15.5.2. Drug Discovery & Development
15.5.3. Personalized Medicine
15.5.4. Disease Risk Assessment
15.5.5. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Type
15.7.3. By Disease Indication
15.7.4. By Application
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Thermo Fisher Scientific Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Qiagen N.V.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. F. Hoffmann-La Roche AG
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Agilent Technologies, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Illumina Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Merck KGaA
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Bio-Techne Corporation
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Siemens Healthineers AG
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. PerkinElmer, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Myriad Genetics, Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Becton, Dickinson and Company
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Danaher Corporation
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. Genomic Health, Inc.
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. Financial Overview
16.3.13.4. SWOT Analysis
16.3.13.5. Strategic Overview
16.3.14. Pacific Biosciences of California, Inc.
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Product Portfolio
16.3.14.3. Financial Overview
16.3.14.4. SWOT Analysis
16.3.14.5. Strategic Overview
16.3.15. Bio-Rad Laboratories, Inc.
16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.15.2. Product Portfolio
16.3.15.3. Financial Overview
16.3.15.4. SWOT Analysis
16.3.15.5. Strategic Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings